Sciety invests in cancer diagnostics of the future with Industrifonden

2020-01-23

Sciety invests SEK 35 million in the company Elypta, which is developing a new method for early cancer diagnosis. The Sciety network together with the Swedish venture capital fund Industrifonden, Chalmers Ventures and several of the company’s existing owners took part in the capitalization. The new capital of a total…

Read more

Sciety network invests in Predicare, the company that aims to streamline emergency care around the world

2019-12-03

The Sciety investment syndicate recently completed an investment of MSEK 9 in Predicare, a company that has developed RETTS––a system used by the majority of Sweden’s emergency units. The new capital will be used to expand in selected European markets and further develop the company’s product portfolio. Gothenburg-based Predicare was…

Read more

Predicare is growing––new customers in Norway

2019-09-26

During September, Predicare finalised an agreement with two new clients in Norway––a hospital and an ambulance services company. Predicare continues to grow rapidly in Norway and their RETTS© system is used by 31 out of 49 hospitals with emergency units. CEO, Mathias Myrén, says: “Predicare has signed an agreement with…

Read more

EMPE Diagnostics raises MSEK 9 for launch in India

2019-08-29

This week, EMPE Diagnostics completed a new share issue of a total of SEK 9.2 million with Sciety. The company has developed a quick test for tuberculosis and the new capital will support the establishment of operations in India where tuberculosis is a major health problem. “With the new capital,…

Read more

The Sciety syndicate invests MSEK 15 in cutting-edge company specializing in DNA sequencing

2019-06-12

This week, Single Technologies completed a new share issue of 15 million SEK with Sciety. The company has developed a DNA sequencing solution, which makes it possible to analyse larger amounts of data faster and cheaper than before. The new capital will be used to adapt the instrument for NGS…

Read more

Athera Biotechnologies raises MSEK 55 with the help of Sciety

2019-05-14

This week, pharmaceutical company Athera Biotechnologies, completed a new share issue of SEK 55 million in which Industrifonden, Östersjöstiftelsen and the Sciety investment syndicate participated. The new capital is to be used for a clinical Phase 2 study and the company aims at being acquired by a major player after…

Read more

Sciety raises new capital for a medtech company to continue their expansion in Europe

2019-04-02

Medtech company Likvor raises new capital for its continued expansion in Europe. They currently have about ten hospitals as clients. The company’s system is used to diagnose the dementia-like disorder, NPH. Likvor has developed a system for the monitoring of cerebrospinal spinal fluid dynamics to investigate and follow up the…

Read more

Sciety raises new capital for pharma company within fat-related diseases

2019-03-26

Lipigon Pharmaceuticals has raised SEK 8 million in a new share issue to finance the continued pre-clinical development of pharmaceuticals within fat-related diseases, so-called lipid-related disorders. Lipid imbalance cause common diseases, such as diabetes and cardiovascular diseases, but also a number of rare diseases currently lacking sufficient treatment. Based on…

Read more

Sciety arranges two private placements

2019-02-11

Sciety is currently capitalizing a Phase II pharmaceutical company and a DNA sequencing tech company––both via private placements. The companies operate in high growth markets and raise new capital to achieve product development goals that will lead to acquisition within the next twenty-four months.     Drug candidate with a…

Read more

New venture at Sciety – develops drugs for diseases caused by high levels of blood lipids

2018-11-26

Lipid imbalances does not only cause common diseases such as diabetes and cardiovascular diseases but also various rare diseases. The pharma company Lipigon is specialised in diseases caused by lipid imbalances, with an initial focus on rare diseases that lack adequate treatments.   New candidate for treatment of severe disease…

Read more